Curated News
By: NewsRamp Editorial Staff
June 25, 2026

VERAXA Biotech Unveils Promising BiTAC-ADC Cancer Data

Discuss on Substack View History of this news story on GitHub
Original Source

TLDR

  • VERAXA Biotech's BiTAC-ADC platform shows selective cancer cell killing, offering a competitive edge in precision oncology partnerships.
  • VERAXA's BiTAC-ADC platform uses antibody-drug conjugates to activate therapeutics only in targeted tumor cells, sparing healthy cells.
  • VERAXA's targeted cancer therapy aims to improve patient outcomes by destroying tumors while reducing harm to healthy cells.
  • VERAXA's BiTAC-ADC destroyed 3D tumor spheroids in lab tests, a promising step toward more effective cancer treatments.

Impact - Why it Matters

This news matters because VERAXA's BiTAC-ADC platform represents a potential breakthrough in cancer treatment, offering a way to kill cancer cells more selectively while reducing damage to healthy cells. For patients, this could mean more effective therapies with fewer side effects, addressing a critical unmet need in oncology. For the industry, it signals a new direction in antibody-drug conjugate design that could lead to safer and more powerful cancer drugs. As VERAXA seeks partnerships, the technology could accelerate the development of next-generation cancer therapies.

Summary

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has announced new in vitro proof-of-concept data supporting its BiTAC-ADC platform, a technology designed to improve the selectivity of antibody-drug conjugates in cancer treatment. The announcement comes as the company prepares to engage with potential pharmaceutical and biotechnology partners during the BIO International Convention 2026 in San Diego. The newly released data showed that VERAXA’s BiTAC-ADC technology was able to distinguish between breast cancer cells and healthy cells in laboratory studies and demonstrated dose-dependent destruction of three-dimensional tumor cell spheroids. While the platform remains in early development, these results mark a significant step toward more targeted cancer therapies that could reduce side effects for patients.

VERAXA’s proprietary BiTAC approach is designed to improve the precision of antibody-based cancer therapies by activating therapeutic effects only in targeted tumor cells. The company is presenting both its BiTAC-ADC and BiTAC-TCE platforms for potential strategic collaborations at the BIO International Convention 2026. VERAXA maintains a diversified oncology pipeline of antibody-based formats including antibody-drug conjugates (ADCs), T-cell engagers (TCEs), and other antibody-based formats. The company recently began trading on the NASDAQ Capital Market under the ticker symbol VRXA following the completion of its business combination with Voyager Acquisition Corp. For more details, the full press release is available at NetworkNewsWire.

The news underscores VERAXA’s commitment to advancing next-generation cancer therapies. With its BiTAC platform, the company aims to address one of the biggest challenges in oncology: targeting cancer cells while sparing healthy tissue. As VERAXA continues to develop its pipeline and seek partnerships, the potential for more effective and less toxic cancer treatments moves closer to reality. Investors and industry observers will be watching closely as the company presents its data at the upcoming BIO International Convention.

Source Statement

This curated news summary relied on content disributed by NewMediaWire. Read the original source here, VERAXA Biotech Unveils Promising BiTAC-ADC Cancer Data

blockchain registration record for this content.